Ren Z, Shao G, Shen J, et al. Serplulimab-HCC Investigators. Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma. Cancer Immunol Immunother. 2025 Jan 3;74(2):69. doi: 10.1007/s00262-024-03917-w. PMID: 39751879; PMCID: PMC11699032.
Cancer Immunology, Immunotherapy
